Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
